



Published in final edited form as:

BMJ Case Rep. ; 2018: . doi:10.1136/bcr-2017-223887.

Pancytopenia: a rare complication of Graves' disease

Vishnu Vardhan Garla, Sohail Abdul Salim, and Licy L Yanes-Cardozo

Internal Medicine, University of Mississippi Medical Center, Jackson, Mississippi, USA

SUMMARY

A 27-year-old male patient who presented to the emergency room with complaints of sweating, palpitations, heat intolerance, insomnia and weight loss for the last 3 months. His medical history was significant for hypertension. On examination, he was tachycardic, hypertensive, had tremors of the upper extremities and a smooth goitre with a thyroid bruit. Laboratory assessment revealed a suppressed thyroid-stimulating hormone, high free thyroxine and positive thyroid receptor antibodies. Complete blood count showed pancytopenia. As part of the work-up for pancytopenia, haptoglobin, ferritin, Coombs test, reticulocyte count hepatitis B and C antibodies were done, all of which were normal. Patient was started on methimazole, propranolol and hydrocortisone. His symptoms improved through the hospital course and he was subsequently discharged. Thyroidectomy was done once the patient's hyperthyroidism was controlled. Levothyroxine was started for the control of postsurgical hypothyroidism. Six months after thyroidectomy, the patient was euthyroid and the pancytopenia resolved.

BACKGROUND

Graves' disease is an autoimmune condition in which antibodies are produced against the thyro-tropin (TSH) receptors on the thyroid gland. Activation of these receptors by thyrotropin receptor antibodies (TRAbs) leads to hyperthyroidism which is clinically characterised by increased appetite, weight loss, palpitations, tremors, hyperdefecation and insomnia.¹

Graves' disease could be associated with a variety of single cell lineage haematological abnormalities including anaemia, thrombocytopenia and leucopenia. However, pancytopenia is a very rare complication of Graves' disease.²

CASE PRESENTATION

A 27-year-old male patient who presented to the emergency department with a 3-month history of sweating, palpitations, heat intolerance, insomnia and weight loss. Medical history was significant for hypertension. Vitals on admission revealed a tachycardia of 113/min,

Correspondence to Dr Vishnu Vardhan Garla, vishnu.garla@gmail.com.

Contributors VVG and SS were involved in writing the manuscript. LY-C was involved in writing the discussion section and editing the manuscript.

Competing interests None declared.

Patient consent Obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

blood pressure of 161/101 mm Hg and a temperature of 97.8°F. Examination revealed an anxious disposition, large smooth goitre with a thyroid bruit and fine tremors of the upper extremities. No exophthalmos or pretibial myxedema was noted.

INVESTIGATIONS

Laboratory assessment revealed a suppressed thyroid-stimulating hormone (TSH) and high free thyroxine. Complete blood count (CBC) done before the initiation of methimazole showed anaemia, leucopenia and thrombocytopenia (table 1). As part of the work-up for pancytopenia, haptoglobin, ferritin, Coombs test, reticulocyte count hepatitis B and C antibodies were done, all of which were normal (table 1). Thyroid peroxidase, TRab and thyroid-stimulating immunoglobulin were positive confirming Graves' disease as the aetiology of hyperthyroidism (table 1). ECG showed sinus tachycardia. Echocardiogram showed an ejection fraction of 55% and normal left ventricular function.

TREATMENT

Patient was started on methimazole, propranolol and hydrocortisone for the treatment of his hyperthyroidism. His symptoms improved through the hospital course and he was subsequently discharged. On follow-up in the clinic, patient continued to experience improvement in his symptoms as well as the blood counts (figure 1). Thyroidectomy was done 2 months after the discharge. Pathology revealed diffuse thyroid hyperplasia compatible with Graves' disease.

OUTCOME AND FOLLOW-UP

Levothyroxine was started for control of post-surgical hypothyroidism. Six months after thyroidectomy, the patient was euthyroid and CBC showed further improvement in the cell count in all cell lines with resolution of pancytopenia (figure 1).

DISCUSSION

Thyroid hormone can affect the haemopoietic system in a number of different ways. While haematological abnormalities are commonly seen in hyperthyroidism clinically significant abnormalities occur infrequently.² We believe that the prevalence of various haematological disorders in hyperthyroidism is underestimated as haematological parameters are not routinely obtained before initiating therapy. Graves' disease could be associated with a variety of single cell lineage haematological abnormalities including anaemia, thrombocytopenia and leucopenia. However, pancytopenia is a very rare complication of Graves' disease.²

Hyperthyroidism causes an increase in the basal metabolic rate as well as oxygen consumption; this causes a relative hypoxia which stimulates the kidneys to secrete erythropoietin.³ Erythropoietin increases the production of red blood cells; however, since there is an increase in the plasma volume as well the haematocrit remains constant.

Hyperthyroidism also causes an increase in 2,3-diphosphoglycerate which decreases the affinity of haemoglobin to oxygen.⁴

Anaemia is noted in 12%–34% of patients with hyper-thyroidism.^{5,6} Microcytic, normocytic and macrocytic anaemias are observed with hyperthyroidism. Microcytic anaemia could be secondary to accelerated erythropoiesis or iron deficiency.³ Normocytic anaemia is sometimes seen in patients with Graves' disease with bone marrow erythroid hyperplasia indicating ineffective erythropoiesis.⁷ Macrocytic anaemia could be secondary to vitamin B12 deficiency or folic acid deficiency.⁸ Pernicious anaemia which is due to the deficiency of intrinsic factor secretion by the parietal cells in the stomach is seen in about 1%–3% of patients with Graves' disease.⁹ Aplastic anaemia can also be secondary to high dose methimazole.¹⁰ Our patient had a normal reticulocyte count, iron studies, vitamin B12, folate, haptoglobin and a negative Coombs test. We believe that the anaemia in our patient could have been secondary to ineffective erythropoiesis.

Leucopenia and neutropenia are seen in about 15%–30% of untreated patients who are hyperthyroid.¹¹ Various mechanisms have been implicated which include a decreased granulocyte reserve, decreased leucocyte circulation time and immunological destruction in cases where the antineutrophil cytoplasmic antibody is present.^{12,13} Agranulocytosis is a well-known side effect of thionamides (methimazole and propylthiouracil).¹⁴ It is important to distinguish these two entities as the latter precludes the use of thionamides which are the mainstay of treatment in hyperthyroidism. We therefore recommend a complete blood count in all patients with hyperthyroidism before starting thionamides.

Thrombocytopenia was first noticed in association with hyperthyroidism about 50 years ago. It was believed to be due to increased destruction of platelets secondary to splenic sequestration or antiplatelet antibodies. Antiplatelet antibodies are seen in about 50% of patients with Graves' disease.¹⁵

We searched PubMed using the following keywords: hyperthyroidism or Graves' disease and pancytopenia. We restricted our search to publications in 'English' and involving 'Human subjects'. Abstract of meetings and unpublished results were not included in our study. The last search was done on 25 November 2017.

The initial search resulted in 27 articles, of which 13 articles were excluded based on the title and abstract. Inclusion criteria was that the pancytopenia be noted prior to the initiation of antithyroid medications. Fourteen articles met the inclusion criteria and were included in table 2.

Pancytopenia is a rare but reported complication of hyperthyroidism. It is due to either decreased production of haemopoietic cells or increased destruction by immunological mechanisms or hypersplenism. As shown in the literature, Graves' disease is the most cause of hyperthyroidism associated with pancytopenia. Achieving euthyroidism regardless of the modality resolves the pancytopenia in most of the cases. It should also be noted that in a majority of the cases the pancytopenia was noted before the diagnosis of hyperthyroidism was made emphasising the importance of performing thyroid function tests in evaluation of pancytopenia.

REFERENCES

1. Melmed S, Polonsky K, Larsen P, et al. Williams textbook of endocrinology. 12th ed. Philadelphia: Elsevier, 2011:362–368.
2. Braverman LE, Utiger RD. Werner and Ingbar's The thyroid; a fundamental and clinical text. 7th ed. Philadelphia: PA: Lippincott-Raven:637–42.
3. Das KC, Mukherjee M, Sarkar TK, et al. Erythropoiesis and erythropoietin in hypo- and hyperthyroidism. *J Clin Endocrinol Metab* 1975;40:211–20. [PubMed: 1117976]
4. Miller LD, Sugarman HJ, Miller WW, et al. Increased peripheral oxygen delivery in thyrotoxicosis: role of red cell 2, 3-diphosphoglycerate. *Ann Surg* 1970;172:1051–8. [PubMed: 4099960]
5. Boitard C, Anciaux-Lespine ML, Eugène C, et al. Anémie et microcytosis au cours de la maladie de Basedow. Discussion physio-pathologique. *Nouv Presse Med* 1979;8:499–502. [PubMed: 582336]
6. Klein M, Weryha G, Kaminsky P, et al. Les manifestations hémalogiques des hyperthyroïdies. *Ann Med Interne* 1993;144:127–35.
7. Lahtinen R Sideroblasts and haemosiderin in thyrotoxicosis. *Scand J Haematol* 1980;25:237–43. [PubMed: 7466312]
8. Burns RW, Burns TW. Pancytopenia due to vitamin B12 deficiency associated with Graves' disease. *Mo Med* 1996;93:368–72. [PubMed: 8772327]
9. Hegazi MO, Ahmed S. Atypical clinical manifestations of graves' disease: an analysis in depth. *J Thyroid Res* 2012;2012:1–8.
10. Thomas D, Moisidis A, Tsiakalos A, et al. Antithyroid drug-induced aplastic anemia. *Thyroid* 2008;18:1043–8. [PubMed: 18816182]
11. Lima CS, Zantut Wittmann DE, Castro V, et al. Pancytopenia in untreated patients with Graves' disease. *Thyroid* 2006;16:403–9. [PubMed: 16646688]
12. Eakin DL, Peake RL, Weiss GB. Effect of therapy on the neutropenia of hyperthyroidism. *South Med J* 1983;76:335–7. [PubMed: 6828901]
13. Weitzman SA, Stossel TP, Harmon DC, et al. Antineutrophil autoantibodies in Graves' disease. Implications of thyrotropin binding to neutrophils. *J Clin Invest* 1985;75:119–23. [PubMed: 3838096]
14. Nakamura H, Miyauchi A, Miyawaki N, et al. Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30 years in Japan. *J Clin Endocrinol Metab* 2013;98:4776–83. [PubMed: 24057289]
15. Hymes K, Blum M, Lackner H, et al. Easy bruising, thrombocytopenia, and elevated platelet immunoglobulin G in Graves' disease and Hashimoto's thyroiditis. *Ann Intern Med* 1981;94:27–30. [PubMed: 6893793]
16. Garcia J, França L, Ellinger V, et al. Marrow hypoplasia: a rare complication of untreated Grave's disease. *Arq Bras Endocrinol Metabol* 2014;58:953–7. [PubMed: 25627052]
17. Jha P, Singh YP, Ghimire B, et al. Pancytopenia in a surgical patient, a rare presentation of hyperthyroidism. *BMC Surg* 2014;15:108.
18. Imai K, Ohkuchi A, Nagayama S, et al. Pancytopenia in the first trimester: An indicator of hidden hyperthyroidism. *J Obstet Gynaecol Res* 2015;41:1991–4. [PubMed: 26311610]
19. Loh HH, Tan F. Pancytopenia in a Patient with Grave's Disease. *Med J Malaysia* 2013;68:372–3. [PubMed: 24145274]
20. Chen YH, Lin HJ, Chen KT. Rare presentations of hyperthyroidism--Basedow's paraplegia and pancytopenia. *Am J Emerg Med* 2009;27–258.e1–258.e2.
21. Hegazi M, Kumar R, Bitar Z, et al. Pancytopenia related to Graves' disease. *Ann Saudi Med* 2008;28:48–9. [PubMed: 18299644]
22. Akoum R, Michel S, Wafic T, et al. Myelodysplastic syndrome and pancytopenia responding to treatment of hyperthyroidism: peripheral blood and bone marrow analysis before and after antihormonal treatment. *J Cancer Res Ther* 2007;3:43–6. [PubMed: 17998720]
23. Kebapcilar L, Ye il S, Bayraktar F, et al. Recovery from pancytopenia and liver dysfunction after administration of propylthiouracil for Graves' disease. *N Z Med J* 2005;118:U1615. [PubMed: 16132076]

24. Shaw B, Mehta AB. Pancytopenia responding to treatment of hyperthyroidism: a clinical case and review of the literature. *Clin Lab Haematol* 2002;24:385–7. [PubMed: 12452820]
25. Soeki T, Tamura Y, Kondo N, et al. A case of thyrotoxicosis with pancytopenia. *Endocr J* 2001;48:385–9. [PubMed: 11523911]
26. Ladwig P, Coles R, Fischer E, et al. Thyrotoxicosis in pregnancy presenting as pancytopenia. *Aust N Z J Obstet Gynaecol* 1995;35:457–60. [PubMed: 8717580]
27. Talansky AL, Schulman P, Vinciguerra VP, et al. Pancytopenia complicating Graves' disease and drug-induced hypothyroidism. *Arch Intern Med* 1981;141:544–5.

Learning points

- Hyperthyroidism can be associated with haematological abnormalities (leucopenia, anaemia, thrombocytopenia and pancytopenia) and therefore a complete blood count (CBC) evaluation should be obtained at diagnosis before giving antithyroid medications.
- Thionamides can be safely given in hyperthyroidism-induced pancytopenia; however, close monitoring with CBC is warranted.
- Most of the haematological abnormalities normalise with the treatment of hyperthyroidism.
- In evaluation of unexplained pancytopenia, thyroid evaluation needs to be considered.




Figure 1. Trends in free T4, white cell count (WCC), platelets and haemoglobin before and after total thyroidectomy.

Table 1

Laboratory assessment on admission

Sl no.	Test	Result
1.	TSH (0.27–4.2 mIU/mL)	0.01
2.	FT4 (0.9–1.7 ng/dL)	>7.7
3.	TRab (0–1.75 IU/L)	33
4.	TSI (<1.3TSI Index)	3
5.	TPO (<5.6 IU/mL)	123.38
6.	Haemoglobin (13–17 g/dL)	9.5
7.	White cell count ($4–10 \times 10^9/L$)	2.7
8.	Platelets ($150–400 \times 10^9/L$)	124
9.	Ferritin (30–400 ng/mL)	116
10.	Coombs test	Negative
11.	Haptoglobin (30–200 mg/dL)	113
12.	Reticulocyte count (0.5%–2.3%)	2
13.	Hepatitis B surface antigen	Negative
14.	Antihepatitis C virus RNA	Undetected
15.	Antiplatelet antibodies	Undetected
16.	HIV antibody	Undetected

FT4, free thyroxine; TPO, thyroid peroxidase antibody; TRab, antithyrotropin receptor antibodies; TSH, thyroid-stimulating hormone; TSI, thyroid-stimulating immunoglobulin.

Table 2

Literature review^{11, 16–27}

Sl no.	Authors	Age	Sex	Aetiology	Treatment	Time to recovery of blood counts
1	Garcia <i>et al</i> ⁶	54	F	Graves' disease	RAI	3 months
2	Jha <i>et al</i> ⁷	62	F	Unknown	Unknown	10 days
3	Imai <i>et al</i> ⁸	33	F	Graves' disease	PTU	1 month
4	Loh and Tan ¹⁹	48	M	Graves' disease	RAI	Unknown
5	Chen <i>et al</i> ²⁰	36	F	Unknown	Unknown	4 days
6	Hegazi <i>et al</i> ²¹	43	F	Graves' disease	Unknown	Unknown
7	Akoum <i>et al</i> ²²	65	F	Toxic multinodular goitre	Carbimazole	2 months
8	Lima <i>et al</i> ¹	71	M	Graves' disease	RAI	1 month
		35	F	Graves' disease	Methimazole	6 months
		39	M	Graves' disease	Methimazole	3 months
		18	F	Graves' disease	Methimazole	>1 year
9	Kebapcilar <i>et al</i> ²³	53	F	Graves' disease	PTU	
10	Shaw and Mehta ²⁴	46	M	Graves' disease	Carbimazole	Few weeks
11	Soeki <i>et al</i> ⁵	49	M	Graves' disease	Methimazole	3 months
12	Burns and Burns ⁸			Graves' disease		
13	Ladwig <i>et al</i> ²⁶	25	F	Graves' disease	PTU	Lost to follow-up
14	Talansky <i>et al</i> ⁷	48	F	Graves' disease	RAI	10 months

RAI, radioiodine ablation; PTU, propylthiouracil.